As shares tank, Orchard once again restructures, shedding gene therapy programs and a large part of the staff

John Carroll

Editor & Founder

Almost exactly 2 years ago, Orchard Therapeutics execs reorganized the pipeline, shed staff and circled their wagons around what they considered the most vital part …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

As shares tank, Orchard once again restructures, shedding gene therapy programs and a large part of the staff

John Carroll

Editor & Founder

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Trump’s science crackdown hits rare disease research: ‘We need to sit down with Elon Musk’

Exclusive: Infectious disease doctors consider 'mini-ACIP' if RFK erodes CDC vaccine panel

At least seven drugmakers say they will participate in round two of IRA negotiations

Lilly joins molecular glue field with Magnet deal worth up to $1.25B

Pacira absorbs GQ Bio for $32M; Layoffs at BMS, Eisai and CRISPR Therapeutics

How AI can address ongoing challenges in the life sciences industry

As shares tank, Or­chard once again re­struc­tures, shed­ding gene ther­a­py pro­grams and a large part of the staff

Editor & Founder

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

As shares tank, Orchard once again restructures, shedding gene therapy programs and a large part of the staff